The mission of the High-throughput Library Screening (HTLS) Core is to bring chemical biology, functional genomics and early phase drug discovery to NINDS USERs. Chemical biology and functional genomics together bring a powerful approach to deciphering signaling pathways that control complex biological problems, and though high throughput screening (HTS) develop novel pharmacological compounds for in vivo applications, such as studying the neurological function of newly discovered proteins and validating candidate compounds as drug candidates. This core will support NINDS investigators'development of druggable targets and lead compounds for new treatments of neurological disorders. The cornerstone of this core is the existing high-throughput (HT) library screening and functional genomics capability of the Sanford-Burnham Medical Research Institute (SBMRI). HT library screening is not generally available to academic investigators, so this facility provides a new and unique approach toward characterizing proteins and signaling pathways involved in many aspects of neural development and neurologic disease. This core has been operational as part of the SBMRI Cancer Center for over six years and was heavily used by La Jolla neuroscientists under the auspices of the La Jolla Neuroscience Center NIH Blueprint Core Grant for the past four years, and without this grant there would have been no access to the HTS Core Facility by neuroscientists. The present NINDS P30 application will continue to permit high priority access to NINDS neuroscientists at internal charge-back rates. SBMRI has committed >$110 million investment in equipment, including the robotic screening facility and HT microscopes (for high-content screening), and chemical and siRNA/microRNA libraries, providing significant value-added benefit to NINDS.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Center Core Grants (P30)
Project #
5P30NS076411-03
Application #
8525472
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
3
Fiscal Year
2013
Total Cost
$247,735
Indirect Cost
$84,934
Name
Sanford-Burnham Medical Research Institute
Department
Type
DUNS #
020520466
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Mann, Aman P; Scodeller, Pablo; Hussain, Sazid et al. (2018) Publisher Correction: Identification of a peptide recognizing cerebrovascular changes in mouse models of Alzheimer's disease. Nat Commun 9:1070
Ryan, Tammy; Bamm, Vladimir V; Stykel, Morgan G et al. (2018) Cardiolipin exposure on the outer mitochondrial membrane modulates ?-synuclein. Nat Commun 9:817
Chen, Shanyan; Cui, Jiankun; Jiang, Tao et al. (2017) Gelatinase activity imaged by activatable cell-penetrating peptides in cell-based and in vivo models of stroke. J Cereb Blood Flow Metab 37:188-200
Nagar, Saumya; Trudler, Dorit; McKercher, Scott R et al. (2017) Molecular Pathway to Protection From Age-Dependent Photoreceptor Degeneration in Mef2 Deficiency. Invest Ophthalmol Vis Sci 58:3741-3749
Nagar, Saumya; Noveral, Sarah M; Trudler, Dorit et al. (2017) MEF2D haploinsufficiency downregulates the NRF2 pathway and renders photoreceptors susceptible to light-induced oxidative stress. Proc Natl Acad Sci U S A 114:E4048-E4056
Huang, Timothy Y; Zhao, Yingjun; Jiang, Lu-Lin et al. (2017) SORLA attenuates EphA4 signaling and amyloid ?-induced neurodegeneration. J Exp Med 214:3669-3685
Mann, Aman P; Scodeller, Pablo; Hussain, Sazid et al. (2017) Identification of a peptide recognizing cerebrovascular changes in mouse models of Alzheimer's disease. Nat Commun 8:1403
Tu, Shichun; Akhtar, Mohd Waseem; Escorihuela, Rosa Maria et al. (2017) NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism. Nat Commun 8:1488
Oh, Chang-Ki; Sultan, Abdullah; Platzer, Joseph et al. (2017) S-Nitrosylation of PINK1 Attenuates PINK1/Parkin-Dependent Mitophagy in hiPSC-Based Parkinson's Disease Models. Cell Rep 21:2171-2182
Satoh, Takumi; Lipton, Stuart (2017) Recent advances in understanding NRF2 as a druggable target: development of pro-electrophilic and non-covalent NRF2 activators to overcome systemic side effects of electrophilic drugs like dimethyl fumarate. F1000Res 6:2138

Showing the most recent 10 out of 111 publications